Home
News

Press Releases

June 11, 2024

­­­QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors

Read More
June 3, 2024

­­­QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD

Read More
March 12, 2024

QurAlis to Present at the Stifel 2024 CNS Days

Read More
March 4, 2024

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia

Read More
February 5, 2024

QurAlis to Participate in Upcoming Investor Conferences in February

Read More
January 3, 2024

QurAlis Strengthens Global Presence With Opening of European Headquarters That Includes R&D Manufacturing

Read More
November 29, 2023

QurAlis to Present Data That Show TDP-43 Pathology Drives Loss of Synaptic UNC13A Function in Neurodegenerative Diseases Including ALS and Frontotemporal Dementia

Read More
November 20, 2023

QurAlis to Present at the Piper Sandler 35th Annual Healthcare Conference

Read More
September 6, 2023

QurAlis to Present Data Showing Link Between TDP-43 Pathology and Role of UNC13A in Neuronal Biology Related to ALS and Other Neurodegenerative Diseases

Read More
July 11, 2023

QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

Read More
June 27, 2023

QurAlis and Unlearn Announce Collaboration to Accelerate and Optimize ALS Clinical Trials With Generative Artificial Intelligence Technologies

Read More
June 8, 2023

QurAlis’ FlexASOs Show High Potency and Improved Safety Over Standard ASOs

Read More
June 6, 2023

QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

Read More
June 1, 2023

QurAlis to Participate in Upcoming Investor Conferences in June

Read More
April 6, 2023

QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

Read More
March 20, 2023

QurAlis Reveals Newest Program Targeting UNC13A RNA Mis-splicing Incorporating its FlexASO™ Platform

Read More
March 9, 2023

QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases

Read More
January 5, 2023

QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS

Read More
December 8, 2022

QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

Read More
September 13, 2022

QurAlis to Present at 22nd Annual Biotech in Europe Forum

Read More
July 27, 2022

QurAlis to Present at H.C. Wainwright Private Company Showcase

Read More
June 21, 2022

QurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board

Read More
May 25, 2022

QurAlis Presents at ALS Drug Development Summit 2022

Read More
March 22, 2022

QurAlis to Present at H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference

Read More
March 15, 2022

QurAlis Presents Data About STATHMIN-2 Role in Neuronal Disease Biology and TDP-43 Biomarker Identification at AD/PD™ 2022

Read More
February 8, 2022

QurAlis Hires Key Regulatory Affairs, Clinical Operations, and Global Supply Chain Management Experts to Support Strategic Objectives

Read More
January 3, 2022

QurAlis to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

Read More
December 22, 2021

QurAlis Announces Publication in Molecular Biology of the Cell of Next Generation Drug Screening Platform for ALS Developed by Company Founders

Read More
December 6, 2021

QurAlis Presents New Data Confirming Role of STATHMIN-2 in Neuronal Disease Biology at 32nd International Symposium on ALS/MND

Read More
November 18, 2021

QurAlis to Present at 33rd Annual Piper Sandler Virtual Healthcare Conference

Read More
September 14, 2021

QurAlis Announces Development Candidate for ALS Targeting STATHMIN-2

Read More
June 8, 2021

Cell Reports Publishes Discovery Data Supporting the Importance of Ion Channel, Kv7.2/7.3 as a Therapeutic Target in ALS

Read More
May 26, 2021

QurAlis Boosts World-Class Leadership Team with Addition of Three New Members

Read More
February 2, 2021

QurAlis Continues to Expand Leadership Team with Two Key Hires

Read More
December 10, 2020

QurAlis’ Selective Kv7 Opener, a Drug Candidate for ALS, Demonstrates up to 20-Fold Increase in Potency and Dramatic Reduction in Side Effects Compared to Retigabine in Preclinical Models

Read More
December 2, 2020

QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1) at MNDA 31st International Symposium on ALS/MND

Read More
October 29, 2020

QurAlis Announces Appointment of new Chief Medical Officer and Formation of Clinical Advisory Board

Read More
July 1, 2020

QurAlis Announces Agreement to Strengthen ALS Pipeline

Read More
May 13, 2020

QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS)

Read More
April 5, 2018

QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria, united in the fight to cure ALS

Read More
December 15, 2017

QurAlis has won the Amgen Golden Ticket at LabCentral

Read More

Explore More

Latest Press Releases